GlassScriptPhysician profile
Joyce L Johnson
NPI 1336598895
$12,496.71
in general payments reported to CMS, 2019-2025
22 companies · $1,833 in 2025
The $1,833 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,607 · 2022: $3,800 · 2023: $4,506 · 2024: $751 · 2025: $1,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,208 · Consulting Fee: $2,310 · Travel and Lodging: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,207.96 |
| Consulting Fee | $2,310.00 |
| Travel and Lodging | $1,571.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $8,642.20 | 2021-2025 | Epclusa |
| Abbvie INC. | $1,627.42 | 2021-2025 | |
| Braeburn INC. | $489.19 | 2023-2025 | Brixadi |
| Indivior INC. | $410.28 | 2021-2025 | Sublocade |
| Alkermes, INC. | $219.45 | 2021-2025 | Lybalvi, Vivitrol, Vivitrol |
| Axsome Therapeutics, INC. | $177.27 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $159.21 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $156.94 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $143.25 | 2025 | Spravato |
| Medtronic, INC. | $91.36 | 2021-2022 | |
| Glaxosmithkline, LLC. | $75.56 | 2021-2022 | |
| Uswm, LLC | $70.71 | 2022-2023 | Lucemyra |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Vanda Pharmaceuticals INC. | $32.96 | 2024 | Fanapt |
| Orexo US, INC. | $28.77 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pear Therapeutics (US), INC. | $27.22 | 2022 | |
| Pfizer INC. | $23.71 | 2021 | |
| Tris Pharma INC | $19.84 | 2024 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $18.64 | 2024 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $17.69 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.88 | 2023 | Quviviq |
| Corium, LLC | $13.16 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.